Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

NCT02983045 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT02983045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Nektar Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
December 19, 2016
Completion date
April 28, 2022
Enrollment
557 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, hr+/her2- breast cancer, melanoma, non small cell lung cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma